IL6 and acute monocytic leukemia: Using a human acute monocytic leukemia cell line THP-1, HM has been demonstrated to exert immuno-modulatory properties through the secretion of interleukin 6 (IL6), and of tumor necrosis factor alpha (TNFα), both anti-tumoral cytokines that contribute to tumor regression, following the activation of transmembrane toll-like receptor 4 (TLR4) [12–15].